Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children

被引:21
|
作者
de Celles, Matthieu Domenech [1 ]
Rohani, Pejman [2 ,3 ,4 ]
King, Aaron A. [5 ,6 ,7 ]
机构
[1] Univ Versailles St Quentin Yvelines, Inst Pasteur, INSERM,U1181, Biostat Biomath Pharmacoepidemiol & Infect Dis Un, Versailles, France
[2] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA
[3] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA
[4] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA 30602 USA
[5] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA
[7] Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
UNITED-STATES; WHOLE-CELL; CHANGING EPIDEMIOLOGY; WANING PROTECTION; IMMUNIZATION; IMPACT; RESURGENCE; TRANSMISSION; ADOLESCENTS; ENGLAND;
D O I
10.1001/jamapediatrics.2019.0711
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
IMPORTANCE The United States has experienced a nationwide resurgence of pertussis since the mid-1970s, despite high estimated vaccine coverage. Short-lived immunity induced by diphtheria-tetanus-acellular pertussis (DTaP) vaccines in young children is widely believed to be responsible for this growing burden, but the duration of protection conferred by DTaP vaccines remains incompletely quantified. OBJECTIVE To assess the duration of immunity and the effectiveness of DTaP vaccines in US children. DESIGN, SETTING, AND PARTICIPANTS A mathematical, age-structured model of pertussis transmission, previously validated empirically on incidence data in Massachusetts, was used in this simulation study to assess the duration of DTaP immunity most consistent with the empirical values of the relative increase in the odds of acquiring pertussis from recent epidemiologic studies in the United States. The study included 5 simulated cohorts of children born between January 1, 2001, and December 31, 2005, followed up between the ages of 5 and 9 years (study period, January 1, 2006, to December 31, 2014). Statistical analysis was performed from May 1 to December 1, 2017. INTERVENTIONS Vaccination with DTaP according to the US immunization schedule, with a range of assumptions regarding the degree of waning immunity. MAIN OUTCOMES AND MEASURES Vaccine effectiveness and relative change in the odds of acquiring pertussis (odds ratio) in children aged 5 to 9 years, duration of DTaP immunity, and vaccine population-level impact. RESULTS This study found a marked association between the degree of waning immunity, vaccine effectiveness, and the odds ratio. Counterintuitively, the odds ratio was positively associated with vaccine effectiveness, as a consequence of nonlinear, age-assortative transmission dynamics. Based on the empirical odds ratios (1.33; 95% CI, 1.23-1.43), it was estimated that vaccine effectiveness exceeded 75% in children aged 5 to 9 years and that more than 65% of children remained immune to pertussis 5 years after the last DTaP dose. CONCLUSIONS AND RELEVANCE The results of this study suggest that temporal trends in the odds of acquiring pertussis are an unreliable measure of the durability of vaccine-induced protection. They further demonstrate that DTaP vaccines confer imperfect, but long-lived protection. Control strategies should be based on the best available estimates of vaccine properties and the age structure of the transmission network.
引用
收藏
页码:588 / 594
页数:7
相关论文
共 50 条
  • [1] Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy
    Greenberg, DP
    Pickering, LK
    Senders, SD
    Bissey, JD
    Howard, RA
    Blatter, MM
    Reisinger, K
    Pichichero, ME
    Howe, BJ
    [J]. PEDIATRICS, 2002, 109 (04) : 666 - 672
  • [2] Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
    Howe, BJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22): : 1803 - 1803
  • [3] Diphtheria-tetanus-acellular pertussis (DTaP) vaccine - Reply
    Marwick, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22): : 1804 - 1804
  • [4] Overview of the clinical development of a diphtheria-tetanus-acellular pertussis vaccine
    Bogaerts, H
    Capiau, C
    Hauser, P
    Mareschal, JC
    Melot, V
    Simons, D
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 174 : S276 - S280
  • [5] Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults
    Van Damme, P
    Burgess, M
    [J]. VACCINE, 2004, 22 (3-4) : 305 - 308
  • [6] Interfering effect of diphtheria-tetanus-acellular pertussis combined (DTaP) vaccines on the bacterial endotoxin test
    Ochiai, M
    Yamamoto, A
    Kataoka, M
    Toyoizumi, H
    Horiuchi, Y
    [J]. BIOLOGICALS, 2001, 29 (01) : 55 - 58
  • [7] Ultrasound examination of extensive limb swelling reactions after diphtheria-tetanus-acellular pertussis or reduced-antigen content diphtheria-tetanus-acellular pertussis immunization in preschool-aged children
    Marshall, Helen Siobhan
    Gold, Michael Steven
    Gent, Roger
    Quinn, Patrick John
    Piotto, Lino
    Clarke, Michelle Frances
    Roberton, Donal Muir
    [J]. PEDIATRICS, 2006, 118 (04) : 1501 - 1509
  • [8] Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations
    Walter, Emmanuel B.
    Klein, Nicola P.
    Wodi, A. Patricia
    Rountree, Wes
    Todd, Christopher A.
    Wiesner, Amy
    Duffy, Jonathan
    Marquez, Paige L.
    Broder, Karen R.
    [J]. PEDIATRICS, 2020, 145 (03)
  • [9] Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines
    Tozzi, AE
    Anemona, A
    Stefanelli, P
    Salmaso, S
    degli Atti, MLC
    Mastrantonio, P
    Giammanco, A
    [J]. PEDIATRICS, 2001, 107 (02) : E25
  • [10] Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations
    Prevot, Adam A.
    Wisner, Elizabeth L.
    [J]. PEDIATRICS, 2020, 146 : S379 - S379